2012 Leadership in Pharmaceuticals & Biotechnology
2012 Leadership in Pharmaceuticals & Biotechnology
June 14, 2012 - New York, NY
JOIN LIKE-MINDED PROFESSIONALS IN YOUR FIELD FOR A FULL DAY OF LEARNING. EXPLORE CUTTING EDGE CONTENT AND EXPAND YOUR NETWORK WITH THE BEST AND BRIGHTEST EXECUTIVES IN THE REGION!
Why You Should Attend!
The pharmaceutical and biotech industries are in the midst of significant change- change in the innovation process, new markets of interest and changes in the financing model. These changes have prompted continued discussion on the future of investment in the sector as well as discussion as to where new opportunities may lie.
On June 14th, when Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology meeting, taking place in Manhattan, life science leaders will meet to discuss the full implications of these changes.
This event will feature insights from top
Endo Pharmaceuticals View Bio »
Robert Cobuzzi Jr., Ph.D. is Senior Vice President, Corporate Development of Endo Pharmaceuticals. Dr. Cobuzzi joined Endo in 2005 with initial responsibility as Senior Director and then Vice President of Scientific Evaluation. In 2008, he was named Acting Head of Corporate Development and was named Senior Vice President in 2010. Before joining Endo, Dr. Cobuzzi was Director, Scientific Licensing at Adolor Corporation, which he joined in 2001. From 1999 to 2001, Dr. Cobuzzi was in the regulatory affairs group at Centocor/Johnson & Johnson and prior to this position, he was part of the cardiovascular clinical team at AstraMerck from 1995 to 1999.
Dr. Cobuzzi received his Ph.D. in molecular and cellular biochemistry from Loyola University Chicago, and a Bachelor of Arts degree in art history from Colby College.
Catalent Pharma Solutions View Bio »
Mr. Cohen is the head of Corporate Development at Catalent Pharma Solutions, a Blackstone portfolio company. Upon joining the company in 2010, he worked with the executive team and Board of Directors to define and implement Catalent’s inorganic strategy supporting Catalent’s transition from pharmaceutical outsourcing provider to the leading provider of development solutions and advanced delivery technologies for the global pharmaceutical, biotechnology and consumer health industries. Known for getting transactions across the finish line, Mr. Cohen is an accomplished M&A practitioner, having worked with and advised companies in the execution of M&A transactions valued at over $75 billion throughout his career.
Since moving to industry, Mr. Cohen has led several successful complex and transformational transactions including divestitures of Catalent’s Printed Components and North American Packaging businesses, acquisition of Aptuit Clinical Trial Supplies and the acquisition, from Gelita AG, of the remaining 49% minority interest in Catalent’s German softgel joint-venture. In addition, Mr. Cohen led the structuring and execution of an innovative transaction with Redwood Bioscience in which Catalent acquired a minority stake, exclusive license to Redwood’s antibody drug conjugate technology and an option to acquire the remaining shares (the option was exercised in October 2014). He been active in emerging markets M&A, spearheading Catalent’s China entry via a joint venture with ShangPharma and the acquisition of a majority-stake in Zhejiang Jiang Yuan Tang Biotechnology and executing the acquisition of Relthy Laboratorios, a softgel manufacturer based in Indaiatuba, Brazil. He also has experience evaluating the acquisition and monetization of pharmaceutical products, having completed multiple transactions, most recently the acquisition of US manufacturing rights to a propranolol ER ANDA marketed by Breckenridge Pharmaceuticals.
Prior to Catalent, Mr. Cohen was a Managing Director and head of Healthcare M&A at Oppenheimer & Co. where he was a member of the valuation and fairness opinion committees. From 1998-2009, he was a member of Bear Stearns and J.P. Morgan’s healthcare and M&A groups. Daniel graduated Magna Cum Laude from the Sy Syms School of Business at Yeshiva University.
AVI BioPharma View Bio »
Chris joined AVI as President and Chief Executive Officer on January 1, 2011. He has served as a director of the Company since June 2010. Previously he was Vice President of Corporate Strategy for Celgene Corporation from July 2007. From November 2005 to June 2007, Chris served as an independent consultant to early stage biopharmaceutical companies. From 1997 to 1998 and from 1999 to November 2005, he worked at Gilead Sciences, Inc., where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. Chris also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994. Chris received his BS in marketing from the University of Maryland.
Kaye Scholer View Bio »
Adam Golden is a Partner in and Co-Chair of the Corporate Department of Kaye Scholer LLP. A leader in Kaye Scholer’s esteemed Life Sciences practice, Mr. Golden heads the firm’s Life Sciences Transactions group.
Mr. Golden's practice focuses on structuring and negotiating complex business transactions, including mergers and acquisitions, joint ventures, and the full range of licensing and collaboration transactions common to the life sciences sector. He has also represented both issuers and investors in public and private securities offerings, including venture capital, private equity and PIPE financings.
Mr. Golden has substantial experience representing clients for whom intellectual property is a key asset. As a lawyer with a background in science, he brings an in-depth understanding of the technology involved in transactions for the benefit of his clients. His clients include companies in the pharmaceutical and biotechnology, chemicals, information technology, healthcare services and medical devices industries. Mr. Golden’s practice is international in scope, and his clients range in size from multibillion-dollar global businesses to emerging-stage companies.
Chambers USA (2009–2011) recognized Mr. Golden and rated Kaye Scholer’s multidisciplinary Life Sciences practice as being among the strongest in the nation, winning praise for “comprehensive service” with a “results-oriented approach and deep understanding of the market.” According to a source interviewed by Chambers, Mr Golden “understands the industry like no other lawyer.”
Novartis View Bio »
Milton Grannatt is Vice President and Head, Search & Evaluation and Negotiations for Respiratory in Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex service, an acquisitive, diversified UK-based company. Dr Grannatt has an extensive deal sheet.
Dr Grannatt received his undergraduate degree and PhD in Economics from Lehigh University.
PwC View Bio »
Jonathan Isler is a partner in PricewaterhouseCoopers’ Transaction Services group specializing in providing valuation and transaction accounting advice to corporate and private equity entities. He specializes in assisting clients maximize investment returns through optimal transaction diligence and structuring, with a focus on such areas as valuation matters, purchase accounting, leverage buy-outs, recapitalizations, joint ventures and compensation plan design. Additionally, Jonathan specializes in the valuation of businesses, intangible assets and financial instruments primarily related to financial reporting and tax matters. Jonathan has worked with clients on a global basis in numerous industries including entertainment and media, pharmaceutical and healthcare, asset management, telecommunications, software and technology, Furthermore, Jonathan has specialized in assisting companies during periods of corporate reorganization and upon emergence from Chapter 11. He has worked with several companies in providing valuation and accounting advisory services associated with fresh-start reporting and other related matters.
In addition to Jonathan’s transactional experiences, he has provided strategic consulting services to clients in the Entertainment, Media and Communications industry advising on potential new markets, valuation metrics and operational and integration matters.
Jonathan received his M.B.A. from Columbia Business School and his B.S., Accounting, from University at Albany. Jonathan is also a Certified Public Accountant in New York. Furthermore, Jonathan is a frequent speaker on transaction accounting and valuation matters at NYU's Stern School of Business and other forums for clients and industry professionals. He also has published thought leadership pieces on such items as emerging trends in transaction accounting and valuation matters.
Acorda Therapeutics Inc. View Bio »
Ruhi Khan is an experienced Corporate Development/Business Development and Finance professional focused on the Biotechnology and Pharmaceuticals industries with over 15 years of experience in sourcing, structuring, negotiating and managing licensing, financing and strategic alliance transactions. Ms. Khan joined Acorda in February 2009 and is responsible for corporate and business development, alliance management, competitive intelligence and business strategy. Before Acorda, Ms. Khan was at Lexicon Pharmaceuticals where she was responsible for initiating and executing business development transactions licensing technologies and products. Prior to joining Lexicon, Ms. Khan was a Director at Fidelity Biosciences, the healthcare venture capital arm of Fidelity Investments, and had an active role in investments in Ironwood Pharmaceuticals and EnVivo Pharmaceuticals concurrently serving as Director of Business Development and Finance for EnVivo. Previous to Fidelity Biosciences, she was an analyst at MPM Capital Advisors, and a healthcare consultant with the Axon Group. Ms. Khan holds a B.A. in Biology from Harvard University and an M.B.A. from the Wharton School of the University of Pennsylvania.
PwC View Bio »
Anup is a Director in the PricewaterhouseCoopers' Pharmaceutical & Life Sciences R&D Advisory Services practice with over twelve years of experience working in the pharmaceutical and life sciences industry focused on R&D.
Anup joined PwC in 2004 and leads projects across R&D Strategy, Operations, and Compliance. Anup has spoken at a number of industry conferences on various R&D related topics spanning strategic outsourcing in R&D, organizational and operational alignment across R&D Quality & Compliance, and emerging model for drug and device safety. He is a recognized thought leader and a key author and contributor to several PwC Publications, including Pharma 2020.
Anup has worked with R&D Executives on large scale clinical development transformations, post merger / acquisition integration projects, establishment of academic-industry consortia. Anup has helped to establish our R&D Strategy offerings and leads projects in clinical outsourcing and optimizing patient recruitment. In addition, Anup has been leading our R&D Compliance efforts to help companies deal with traditional quality issues associated with R&D, but also driving initiatives to help R&D organizations get ahead of the curve on monitoring global compliance risks as trials are run in emerging geographies using various staffing models.
Prior to joining PwC, Anup worked in Clinical Development at GSK. His first role was as a Clinical Research Scientist supporting the Human Biomarkers Center that worked with all of the CEDDs to help identify and evaluate biomarkers for use in early development and Pre-POC studies. Previous to GSK, Anup worked as a Research Scientist focused on endometriosis research at Wyeth-Ayerst.
Anup earned his MBA Degree in Healthcare Management from Temple University, MS degree in Pharmacology from Cornell University, and his Bachelor’s degree in Biology from The Pennsylvania State University.
Perrigo Co. View Bio »
Mr. Sharon Kochan is Executive Vice President and GM of the Prescription (Rx) Pharmaceuticals Segment of Perrigo Company, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) with annual sales in excess of $3 Billion.
Sharon started his career in pharmaceuticals with Clay-Park Labs in 1994 as a project manager, and grew through the ranks, and by way of acquisitions, to serve as SVP of Business Development and Strategy for Perrigo Company in March 2005, further to the acquisition of Clay-Park Labs/Agis by Perrigo in March 2005.
In March 2007, Sharon Kochan was promoted to an EVP role with responsibility to lead the Rx Pharmaceuticals segment of Perrigo, which had just over $100M in annual sales at that time. During the last five years the business experienced consistent and impressive growth trajectory, driven both by fruition of an organic pipeline, select product acquisitions and the latest acquisition of Paddock Labs, the Perrigo Rx segment annual sales run rate exceeds $600M based on FY12 H1 with operating margins well above the industry averages.
Sharon Kochan holds a BSc. degree in Industrial Engineering, cum laude, from Tel-Aviv University, and MSc. degree in Operations Research from Columbia University in NYC.
Innography View Bio »
Bob Little brings a strong track record for leading marketing teams to capitalize on innovative applications of technology in life sciences, financial services, corporate governance and litigation. Prior to joining Innography, Bob was Vice President, Marketing at IntraLinks with responsibility for product messaging, go-to-market strategy and demand creation. He was previously Chief Marketing Officer at RenewData, VP of Marketing at ZANTAZ and also General Manager of the Compliance Product Business Unit for Documentum/EMC. Bob holds a BS in Pharmacy Science from Tennessee Technological University.
Bristol-Myers Squibb View Bio »
Ellen Lubman is a Former Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focused on M&A execution and strategy, identification of new transaction opportunities, and initiation of String of Pearlsť transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a private equity fund that acquires direct ownership or controlling stakes in commercially attractive pharmaceutical products in the late stages of clinical and regulatory development, and VIA Pharmaceuticals, a start-up cardiovascular disease biotechnology company incubated at Bay City Capital in San Francisco. During the heyday of the Human Genome Project, Ellen was a Biotechnology Equity Research Analyst at Robertson Stephens where she focused on Genomics, Proteomics, Drug Discovery and Technology Platform companies, and developed research pieces on Genetic Intellectual Property, Single Nucleotide Polymorphisms and other discovery technologies. Ellen holds a bachelor’s degree in Biological Sciences from Rutgers College and an MBA from the Stanford Graduate School of Business, including a Certificate in Global Management. She is a Director on the Board of Gilda's Club of NYC and the Investment Board of Springboard Enterprises.
Sanofi-Aventis View Bio »
Dr. Kenneth Maynard is head of external innovation in the Therapeutic Strategic Unit, Aging at sanofi-aventis U.S. Previously, he spent five years as a project director responsible for leading multifunctional teams in the clinical development of central nervous system (CNS) compounds and five years in CNS research as principal scientist and section head for cerebrovascular disorders.
Prior to joining the pharmaceutical industry, Kenneth was assistant professor in surgery (neurosurgery) at Harvard Medical School and assistant neuroscientist in the neurosurgical service, at Massachusetts General Hospital. He holds BSc, MSc and PhD degrees in the areas of human sciences, neurological science and neurobiology respectively from University College, London, U.K.
Kenneth serves in leadership roles as an elected fellow of the American Heart Association (F.A.H.A.) and the Society for Neuroscience. He also serves on the executive committee of the International Dose-Response Society. He has authored more than 45 scientific publications and serves on the editorial committees of the American Journal of Pharmacology and Toxicology, Current Neurobiological Research, Current Neurovascular Research and Recent Patent Reviews on CNS Drug Discovery.
Johnson & Johnson View Bio »
Garry Neil, M.D. is Corporate Vice President, Corporate Office of Science and Technology (COSAT), Johnson & Johnson. In this role, Garry leads a team that catalyzes sustained growth for Johnson & Johnson by identifying and launching emerging technologies that underpin the creation of future businesses.
Garry has broad experience in science, medicine and pharmaceutical development. He has held a number of senior positions within J&J, most recently Group President, Johnson & Johnson Pharmaceutical Research and Development where he was responsible for maximizing existing strengths and leveraging collective resources to bring innovative new molecular entities (NMEs) to market quickly and cost effectively. Through a number of new initiatives he helped transform J&J’s pharmaceutical R&D to a much more capable and productive organization and helped recruit a number of top scientists. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases, gained initial or new and/or expanded indication approvals.
Garry joined J&J in 2002 as Senior Vice President of Drug Development at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). In 2005, Garry became President of J&JPRD, and in 2006, was promoted to Group President. Before joining J&JPRD, he held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held a number of academic posts at a number of academic institutes including the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa College of Medicine and the University of Pennsylvania (adjunct).
Garry has written more than 50 articles and book chapters. He holds a Bachelor of Science degree from the University of Saskatchewan and a medical degree from the University of Saskatchewan College of Medicine and completed his postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, a member of the American Association of Immunologists, and the Society for Clinical Trials, and a member of the Life Sciences Leadership Council of the University of Michigan. He is a member of the Boards of the Reagan Udall Foundation and the J&J Development Corporation and is J&J’s representative to, and Chairman of, the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee, Chairman of the PhRMA Foundation Board, Chairman of the Scientific Advisory Board of the Center for Advanced Biotechnology and Medicine (Rutgers), and a member of the Executive Committee of the Biomarkers Consortium. He is also the 2007 discovery awardee of the American Geriatrics Society.
Infinity Pharmaceuticals Inc. View Bio »
Adelene Q. Perkins has served as Infinity’s president and chief executive officer since 2009. Ms. Perkins first joined Infinity as chief business officer in 2002 and then served as president from 2008-2009. Since joining Infinity, she has played an integral role in building the company, in leading its transition from a platform- to a product-based organization, and in developing Infinity’s business strategy, including the establishment of innovative strategic partnerships.
Ms. Perkins has more than 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of BIO (Biotechnology Industry Organization) and the Villanova University College of Engineering and is the Vice Chairman of the Board of Project Hope.
Medicis Pharmaceutical Corporation View Bio »
Seth Rodner has a unique combination of government, private practice, and business experience, having served as a federal prosecutor with the U.S. Department of Justice in Washington, D.C., where he specialized in international cartel enforcement; a business crimes litigation partner in a prominent Florida law firm, where his nationwide practice defended a wide range of white collar criminal investigations and agency enforcement proceedings across multiple highly-regulated industries including healthcare and life sciences; and currently Executive Vice President, Chief Legal Officer, and Corporate Secretary for Medicis Pharmaceutical Corporation, an NYSE-listed pharmaceutical, biologics, and medical device company headquartered in Scottsdale, Arizona.
As Medicis’ Chief Legal Officer, Mr. Rodner directs the worldwide legal affairs of the corporation, including its prescription dermatology, facial aesthetics, and orphan drug divisions. His mandate spans all dimensions of the business, ranging from corporate governance, securities disclosure, and FDA regulatory and other healthcare fraud and abuse guidance to transactions, investigations, litigation, contracting, employment, and intellectual property matters.
Mr. Rodner joined Medicis in September 2006 as the Company’s Chief Compliance Officer, and served in that capacity through November 2010, during which period he negotiated, implemented, and oversaw Medicis’ now completed Corporate Integrity Agreement. Mr. Rodner was appointed Medicis’ General Counsel and Corporate Secretary in 2010, and became Executive Vice President and Chief Legal Officer effective January 2012.
A frequent author and speaker on government enforcement and corporate compliance, Mr. Rodner is the past-Chair of the Federal Bar Association’s national Criminal Law Section, and has been named in multiple publications as a rising star in the legal profession. His charitable work includes serving on the Board of the Whispering Hope Ranch Foundation, and prior pro bono service as the Director of the New England Innocence Project, where he coordinated a six state initiative utilizing DNA evidence to exonerate wrongly-convicted individuals. Mr. Rodner was awarded the highest possible AV Peer Review Rating by Martindale-Hubbell for both legal ability and ethical standards, and earned his B.A. from Amherst College in 1991 and J.D. from Duke University in 1994.
Pfizer View Bio »
Pol Vandenbroucke is Vice President, Development, Emerging Markets. Prior to this appointment he was Vice President, Medical and Regulatory Affairs, Canada/Latin America/Africa-Middle East, Vice President, Medical Division Japan, based in Tokyo, and Director of Medical Operations, Asia/Australia/NZ, based in Hong Kong. He moved to Hong Kong from Pfizer HQ in New York where he was a member of the Joint Operating Committee that managed the partnership of Pfizer and Warner-Lambert for Lipitor (atorvastatin), responsible for Pfizer for the international clinical development of Lipitor.
Before joining Pfizer, Pol was US Medical Director, Bayer CC, Medical Director, Sterling-Winthrop International and Cardiovascular Disease Manager at Novartis. His background includes experience in Medical Affairs, Clinical Development and Regulatory experience in the U.S., Europe, Latin America and Asia.
He holds a medical degree and an MBA degree, and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the UK.
A.T. Kearney View Bio »
Michael Wise is A.T. Kearney’s lead for Sustainability in the Americas, and the lead partner for the Boston office. He has fifteen years of consulting experience, spanning strategic and operational engagements with a focus on healthcare and consumer industries.
Michael has worked with Fortune 500 companies on a broad range of sustainability topics including:
- Developing and embedding a corporate sustainability strategy
- Creating sustainable supply chains
- Determining the potential impact of resource scarcity on an organization’s cost structure
He earned a Masters of Management from Northwestern University’s Kellogg Graduate School of Management, and B.S. in biology from the University of Notre Dame.
Aisling Capital View Bio »
Brett Zbar, M.D. serves as a Partner of Aisling Capital, a leading venture capital and private equity firm that also manages the investments of the Perseus-Soros BioPharmaceutical Fund, LP. Aisling Capital invests in life science companies developing biopharmaceutical products and creates businesses based on advanced life science technologies. Dr. Zbar focuses on investments in development-stage as well as commercial-stage companies, and currently serves as a Director or board observer at Aragon Pharmaceuticals, Catalent Pharma Solutions, and Planet Biopharmaceuticals. Previously, Dr. Zbar was an Associate Principal at McKinsey & Company and a senior member of the Pharmaceuticals and Medical Products practice. While at McKinsey, he worked closely with management of large pharmaceutical companies and specialty pharmaceutical companies based in the U.S., Europe and Japan. Prior to joining McKinsey, Dr. Zbar trained on the Osler internal medicine service at Johns Hopkins Hospital. He received his M.D. from Harvard Medical School and his B.A. from Yale College. Dr. Zbar is a member of the Council on Foreign Relations.
8:00am â€“ 9:00am Breakfast
9:00am â€“ 9:05am Argyle Executive Forum Opening Remarks
9:05am â€“ 9:35am "A Walk in the 'Park' This Ain't (or Clean Hands Can Still Be Cuffed): What Every Pharma Executive Needs to Know About RCO Enforcement"
read more »
Seth RodnerExecutive Vice President, Chief Legal Officer & Corporate SecretaryMedicis Pharmaceutical Corporation
9:40am â€“ 10:00am "Winning the Battle for Consumer Healthcare"
read more »
Global demographic changes are creating a new market for consumer-focused products with significant health benefits. This new "consumer healthcare" segment is emerging midway between mass retail-based consumer goods and pharmacy-based pharmaceuticalsâ€”and it will be a new battleground between the giants in these two industries. Which industry will win? It's not yet clear. Consumer goods companies boast strengths in marketing and distribution but are weak on science, an area in which pharmaceutical companies excel. The unique challenges of this new segment will likely require a mixed model, with capabilities from each industry.Michael WisePartner, Vice PresidentA.T. Kearney
10:05am â€“ 10:55am Panel Discussion
read more »
â€śThe Future of R&Dâ€ť
Session topics include, but not limited to:
- New business and financing models for innovation
- Using partnerships to access early stage research and opportunities
- Sharing the risks and costs of new drug development
- New opportunities in the emerging markets
- Partnering with academia
- Open innovation
10:55am â€“ 11:30am Coffee
11:30am â€“ 12:20pm Panel Discussion
read more »
â€śDeal Making in Pharmaceuticals & Biotechnologyâ€ť
Session topics include, but not limited to:
- Current market information and deal drivers
- Recent trends in deal structuring
- The incorporation of risk sharing intro transactions
- Determining which deal structure will lead to the greatest return on your investment
- Key components to consider in valuing a life science asset
12:25pm â€“ 12:55pm "The Rise of the Rare Disease Business Model"
read more »
Chris GarabedianPresident & CEOAVI BioPharma
12:55pm â€“ 1:55pm Lunch
1:55pm â€“ 2:45pm Panel Discussion
read more »
â€śDeveloping an Effective Business Development Strategyâ€ť
Session topics include, but not limited to:
- Latest trends in business development
- Portfolio management as a business development strategy
- Evaluating and negotiating partnerships
- Licensing trends- potential areas for growth
- Managing your pipeline- business developmentâ€™s role
2:50pm â€“ 3:20pm â€śThe U.S. Generic Market - Trends, Opportunities & Issuesâ€ť
read more »
Sharon KochanExecutive Vice PresidentPerrigo Co.
3:25pm â€“ 3:55pm "Navigating the Complexity of 'Convergent' Deals for Healthcare Products and Services"
read more »
Deal making is about solving problems and creating value, for target customers and shareholders. The US and global healthcare markets are evolving rapidly with an enhanced focus placed on the value of care. The value creation equation has consequently changed in a manner that increases Commercialization risk, and thus competition for value-creating assets is reported to be increasing across all segments of healthcare. This presentation will focus on the Endo experience of addressing these issues through deal making that considers the convergence of drugs, devices and services in healthcare delivery.Robert CobuzziSVP Corporate DevelopmentEndo Pharmaceuticals
3:55pm â€“ 4:00pm Argyle Executive Forum Closing Remarks
4:00pm â€“ 5:00pm Cocktail Reception
read more »
*Please note, the agenda is subject to change.
Still have questions? We have answers.
I want to attend, but what if I'm unsure of my schedule and need to cancel my participation?
Just let us know. We understand that schedules
we always have a waiting list for this event,
and if you don't
cancel, we will assume you are still attending
and your spot will
go unused. If you must, cancel at least 48 hours
prior to the
event to make room for others!
What if I can't be OOO for a whole day, or need
to come late?
We have wifi and private rooms available for
attendees to take
calls and spend some quiet time on emails, as
well as access to
printing. Have a morning meeting you can't miss?
No problem. This
event was designed for busy executives - we get
I'd like to bring some colleagues. Do I need to
Events are more fun with friends, and we'd be happy to host your team. You can have them register online, or send us their names, titles and email addresses and we will take care of it for you!
I don't see the event venue listed. Where will
the meeting be
To maintain exclusivity, we don't release the
venue address until
the registration process has been completed. All
details will be shared once you have requested a
pass and been
Traveling for the event? Stay at one of our
Please note the below is a preferred hotel of Argyle Executive Forum. Please specify that you are requesting the Argyle Executive Forum rate when booking sleeping rooms in order to receive a discounted rate of $279.00 per night, taxes not included. Reservations may also be made by emailing firstname.lastname@example.org.
The Fitzpatrick Grand Central
141 E. 44th Street
New York, NY 10017
Telephone: (800) 367-7701
Continuing Education Credits:
Please note that Continuing Education credits are not offered for this meeting